Results 111 to 120 of about 20,923 (159)

Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure. [PDF]

BMC Cardiovasc Disord
Nishikawa T, Nakanishi N, Osawa K, Mizuno J, Ono Y, Shirahata A, Hirabayashi T, Shiba M, Fujiwara R, Kanemitsuya I, Hoshi Y, Noda H, Kadohara H, Ohga Y, Shingu M, Osumi Y, Ishibashi K, Ishii T, Hiraishi M, Kinugasa M, Hirayama Y, Shimokawa T, Matuo M, Tamita K.   +23 more
europepmc   +1 more source

Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy. [PDF]

Cureus
Naik BT, Y S, Patro D, Pankaj S, Gaur M, Paulose G, Kate R, Gude D, Patel A, Sarkar S, Wasil AB, Basu U, Chhabra A, Thyagarajan N, Chavan G, Mate P.   +15 more
europepmc   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. [PDF]

Endocrinol Diabetes Metab
Mohamed ZI, Shidane AA, Abdiasis AM, Hussein MH, Ibrahim AO, Abdi AA, Hashi KI, Mohamud MA, Mohamed AJ.   +8 more
europepmc   +1 more source

Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Karimi M, Tahmasebi A, Ramezanipour S, Rad FN, Valizadeh F, Abedi P, Gholami M, Sobhan Ardekani N, Pirshahid ME.   +8 more
europepmc   +1 more source

Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells. [PDF]

Biomedicines
Szachniewicz M, Baran M, Gagat M, Hałas-Wiśniewska M.   +3 more
europepmc   +1 more source

The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany. [PDF]

Cost Eff Resour Alloc
Hille H, Schramm W, Bounekkar A.
europepmc   +1 more source

The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence. [PDF]

Diabetes Ther
Owczarczyk-Durma AC, Blicharska M, Czupryniak L.   +2 more
europepmc   +1 more source

Effects of Losartan, Empagliflozin, and Their Combination on Uric Acid Concentrations in People With Type 2 Diabetes. [PDF]

Kidney Med
Suijk DLS, Simson PXC, Scholtes RA, Mosterd CM, Hesp AC, Hoorn EJ, Bjornstad P, van Raalte DH.   +7 more
europepmc   +1 more source

Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin. [PDF]

PLoS One
Zhou X, Deng Y, Guo C, Li Y, Fu Y, Wang Z, Dong Z.   +6 more
europepmc   +1 more source

Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage. [PDF]

Cardiovasc Diabetol
Gessner A, Kannenkeril D, Bosch A, Harazny JM, Fromm MF, Klinkhammer H, Staerk C, Mayr A, Schmieder RE, Maas R.   +9 more
europepmc   +1 more source